This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • ALECENSA®▼(alectinib)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼ (pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozlytrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Haematology
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • Evrysdi®▼ (risdiplam)
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab) [Great Britain]
      • Avastin (bevacizumab) [Northern Ireland]
      • Evrysdi®▼(risdiplam)
      • GAZYVARO® (obinutuzumab) Great Britain
      • GAZYVARO® (obinutuzumab) Northern Ireland
      • HEMLIBRA®▼(emicizumab) Great Britain
      • HEMLIBRA®▼(emicizumab) Northern Ireland
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab) GB
      • OCREVUS®▼ (ocrelizumab) NI
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • Rozlytrek® ▼(entrectinib)
      • TECENTRIQ®▼ (atezolizumab) Great Britain
      • Tecentriq®▼ (atezolizumab) Northern Ireland
    • Adverse Event Reporting
      Adverse Event Reporting Overview
    • Home
    • Roche Medicines
      • Oncology
        • ALECENSA®▼(alectinib)
        • Kadcyla® (trastuzumab emtansine)
        • PERJETA® (pertuzumab)
        • PHESGO®▼ (pertuzumab/trastuzumab)
        • TECENTRIQ®▼ (atezolizumab)
        • Rozlytrek▼(entrectinib)
      • Neuroscience
        • OCREVUS®▼ (ocrelizumab)
      • Haematology
        • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
        • Evrysdi®▼ (risdiplam)
        • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      • Oncology
        • Breast Cancer
      • Haematology
        • Haematology
      • Neuroscience
        • Neuroscience
    • Congress and Meetings
    • HCP Materials
    • FAQs
    • Prescribing Information
      • Find out more about:
        • ALECENSA®▼(alectinib)
        • Avastin® (bevacizumab) [Great Britain]
        • Avastin (bevacizumab) [Northern Ireland]
        • Evrysdi®▼(risdiplam)
        • GAZYVARO® (obinutuzumab) Great Britain
        • GAZYVARO® (obinutuzumab) Northern Ireland
        • HEMLIBRA®▼(emicizumab) Great Britain
        • HEMLIBRA®▼(emicizumab) Northern Ireland
        • Herceptin® (trastuzumab) IV
        • Herceptin® (trastuzumab) SC
        • Kadcyla® (trastuzumab emtansine)
        • OCREVUS®▼ (ocrelizumab) GB
        • OCREVUS®▼ (ocrelizumab) NI
        • Perjeta® (pertuzumab)
        • Phesgo®▼(pertuzumab/trastuzumab)
        • Polivy®▼(polatuzumab vedotin)
        • Rozlytrek® ▼(entrectinib)
        • TECENTRIQ®▼ (atezolizumab) Great Britain
        • Tecentriq®▼ (atezolizumab) Northern Ireland
    • Adverse Event Reporting
    • Sign in
    • Logout
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    Haematology

    • Haematology
    • POLIVY®▼ (polatuzumab vedotin) in RR DLBCL
      • Efficacy
      • Safety
      • Dosing
      • Patient flow
      • MOA
      • Expert discussions
    • Gazyvaro® (obinutuzumab)
    • More
      • POLIVY®▼ (polatuzumab vedotin) in RR DLBCL
      • Gazyvaro® (obinutuzumab)

    You are here:

    1. Therapy Areas
    2. Haematology

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

    Prescribing Information Polivy®▼(polatuzumab vedotin)
    Prescribing Information GAZYVARO® (obinutuzumab) Great Britain
    Prescribing Information GAZYVARO® (obinutuzumab) Northern Ireland

    Adverse event reporting and additional monitoring

    Polivy

    Discover more about POLIVY for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

    Gazyvaro

    Discover more about where Gazyvaro is indicated for the treatment of patients with CLL and FL.

    Expert discussions

    Listen to insights on the most up-to-date haematology data, as discussed by experts in the field.

    High Grade Lymphoma

     

    Congress highlights

    Learn more about the key data highlights presented at congresses and how they could impact UK clinical practice.

    For full details, please refer to the Gazyvaro® or Polivy® Summary of Product Characteristics.

    FL, follicular lymphoma; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma.


    M-GB-00005857
    Date of preparation: December 2021

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2022 Roche Products Limited
    • 04.04.2022
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00006977 Date of Preparation April 2022.